adalimumab (up to 9 months exposure)

TERMINATED · PHASE4 · Rheumatoid Arthritis

Study terminated due to low subject enrollment. Safety results consistent with product label.

Scientific benefit, asset-specific safety, ownership and licensing: Unknown without reviewed evidence.

Detailed evidence is available in the local Pro plan simulation.